W. Byon

发表

Reporting guidelines for population pharmacokinetic analyses

C. Tornøe, N. Al-Huniti, K. Dykstra, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.

A. Shenker, C. Frost, Jessie Wang, 2014, British journal of clinical pharmacology.

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation

K. Kowalski, B. Cirincione, C. Frost, 2018, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism

C. Frost, R. Boyd, R. Boyd, 2017, CPT: pharmacometrics & systems pharmacology.

Exposure‐Response Analyses of the Effects of Pregabalin in Patients With Fibromyalgia Using Daily Pain Scores and Patient Global Impression of Change

Kaori Ito, B. Corrigan, D. Ouellet, 2010, Journal of clinical pharmacology.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

C. Frost, Jessie Wang, Y. Barrett, 2013, British journal of clinical pharmacology.

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

A. Shenker, C. Frost, Jessie Wang, 2013, British journal of clinical pharmacology.

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

S. Hohnloser, C. Granger, L. Wallentin, 2020, Circulation.

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

C. Frost, Jessie Wang, F. LaCreta, 2013, Clinical pharmacology : advances and applications.

Reporting guidelines for population pharmacokinetic analyses

C. Tornøe, N. Al-Huniti, K. Dykstra, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study

W. Byon, S. Garonzik, D. Marchisin, 2019, American Journal of Cardiovascular Drugs.

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data

M. Jamieson, P. Gargalovic, C. Russ, 2022, American Journal of Cardiovascular Drugs.

The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.

B. Cirincione, F. LaCreta, R. Boyd, 2017, Pharmacoepidemiology and drug safety.

Randomized, blinded, placebo‐ and positive‐controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval

C. Frost, S. Nepal, R. Reeves, 2015, Journal of clinical pharmacology.

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data

M. Jamieson, P. Gargalovic, C. Russ, 2022, American Journal of Cardiovascular Drugs.

Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY

A. Cohen, W. Byon, T. Taylor, 2021, Advances in Therapy.

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Wonkyung Byon, Charles E. Frost, C. Frost, 2019, Clinical Pharmacokinetics.

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

A. Shenker, C. Frost, Jessie Wang, 2016, American Journal of Cardiovascular Drugs.

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

A. Shenker, C. Frost, Jessie Wang, 2015, British journal of clinical pharmacology.

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance

P Chan, M. Tortorici, W. Byon, 2013, CPT: pharmacometrics & systems pharmacology.

Impact of censoring data below an arbitrary quantification limit on structural model misspecification

Courtney V. Fletcher, Wonkyung Byon, Richard C. Brundage, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Response to Letter to the Editor From Drs. Stöllberger and Finsterer

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects

A. Shenker, C. Frost, S. Nepal, 2018, Journal of clinical pharmacology.

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers

A. D. Rodrigues, M. Dowty, Cheng Chang, 2022, Clinical pharmacology and therapeutics.

Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers

T. McRae, V. Sahasrabudhe, W. Byon, 2021, CPT: pharmacometrics & systems pharmacology.

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

W. Byon, B. He, V. Perera, 2023, CPT: pharmacometrics & systems pharmacology.

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

W. Byon, S. Pan, Theodore C. Lee, 2019, Blood.

Reporting guidelines for population pharmacokinetic analyses

C. Tornøe, N. Al-Huniti, K. Dykstra, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242

Richard E. Carson, David Weinzimmer, Nabeel Nabulsi, 2014, NeuroImage.

Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans

Yifeng Lu, Cheng Chang, Wonkyung Byon, 2011, The AAPS Journal.

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism

C. Frost, R. Boyd, W. Byon, 2017, CPT: pharmacometrics & systems pharmacology.

The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.

B. Cirincione, F. LaCreta, R. Boyd, 2017, Pharmacoepidemiology and drug safety.

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY

A. Cohen, W. Byon, T. Taylor, 2021, Advances in Therapy.